Skip to main content

Advertisement

Table 7 Serious adverse events possibly related to study treatment

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Treatment group Adverse event Grade Number of events
Cilengitide and gemcitabine Myocardial infarction 4 1
  Apoplexia 4 1
  Thrombocytopenia 3 1
  Exanthema 1 1
  Weakness 3 2
  Nausea 3 1
  Anaphylactic reaction 4 1
  Pulmonary embolism 4 1
  Gastrointestinal hemorrhage 3 1
  Hypotension1 3 1
  Erysipelas1 3 1
Gemcitabine Anorexia 3 1
  Exanthema 2 1
  Depression 3 1
  Dyspnea 3 2
  Epistaxis 2 1
  Pneumonia 2 1
  Condition reduced1 3 1
  1. 1Relationship "not assessable" by investigator; therefore, considered to be possibly related.